Genetics of COVID-19
- Authors: Vologzhanin D.A.1,2, Golota A.S.1, Kamilova T.A.1, Shneider O.V.1, Sherbak S.G.1,2
-
Affiliations:
- Saint-Petersburg City Hospital No 40 of Kurortny District
- Saint-Petersburg State University
- Issue: Vol 12, No 1 (2021)
- Pages: 41-52
- Section: Reviews
- URL: https://journals.rcsi.science/clinpractice/article/view/64972
- DOI: https://doi.org/10.17816/clinpract64972
- ID: 64972
Cite item
Abstract
COVID-19 is characterized by a wide range of clinical manifestations, from asymptomatic to extremely severe. At the onset of the pandemic, it became clear that old age and chronic illness were the major risk factors. However, they do not fully explain the variety of symptoms and complications of the SARS-COV-2 coronavirus infection. The research on genetic risk factors for COVID-19 is still at its early stages. A number of mutations and polymorphisms have been identified that affect the structure and stability of proteins — factors of susceptibility to SARS-COV-2 infection, as well as a predisposition to the development of respiratory failure and the need for intensive care. Most of the identified genetic factors are related to the function of the immune system. On the other hand, the genetic polymorphism of the virus itself affects the COVID-19 spread and severity of its course . The genome of the virus accumulates mutations and evolves towards increasing contagiousness, replicative ability and evasion from the host's immune system. Genetic determinants of the COVID-19 infection are potential therapeutic targets. Studying them will provide information for the development of drugs and vaccines to combat the pandemic.
Full Text
##article.viewOnOriginalSite##About the authors
Dmitry A. Vologzhanin
Saint-Petersburg City Hospital No 40 of Kurortny District; Saint-Petersburg State University
Email: volog@bk.ru
ORCID iD: 0000-0002-1176-794X
SPIN-code: 7922-7302
Dr. Sci. (Med.)
Russian Federation, 9B Borisova st., 197706, Saint Petersburg, Sestroretsk; Saint PetersburgAlexandr S. Golota
Saint-Petersburg City Hospital No 40 of Kurortny District
Author for correspondence.
Email: golotaa@yahoo.com
ORCID iD: 0000-0002-5632-3963
SPIN-code: 7234-7870
Cand. Sci. (Med.), Associate Professor
Russian Federation, 9B Borisova st., 197706, Saint Petersburg, SestroretskTatyana A. Kamilova
Saint-Petersburg City Hospital No 40 of Kurortny District
Email: kamilovaspb@mail.ru
ORCID iD: 0000-0001-6360-132X
SPIN-code: 2922-4404
Cand. Sci. (Biol.)
Russian Federation, 9B Borisova st., 197706, Saint Petersburg, SestroretskOlga V. Shneider
Saint-Petersburg City Hospital No 40 of Kurortny District
Email: o.shneider@gb40.ru
ORCID iD: 0000-0001-8341-2454
SPIN-code: 8405-1051
Cand. Sci. (Med.)
Russian Federation, 9B Borisova st., 197706, Saint Petersburg, SestroretskSergey G. Sherbak
Saint-Petersburg City Hospital No 40 of Kurortny District; Saint-Petersburg State University
Email: sgsherbak@mail.ru
ORCID iD: 0000-0001-5047-2792
Dr. Sci. (Med.), Professor
Russian Federation, 9B Borisova st., 197706, Saint Petersburg, Sestroretsk; Saint PetersburgReferences
- WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. Avalable from: https://covid19.who.int/
- Ahmadian E, Khatibi SM, Soofiyani SR, et al. COVID-19 and kidney injury: pathophysiology and molecular mechanisms. Rev Med Virol. 2020;e2176. doi: 10.1002/rmv.2176
- Sakurai A, Sasaki T, Kato S, et al. Natural history of asymptomatic SARS-CoV-2 infection. N Engl J Med. 2020;383(3):885–886. doi: 10.1056/NEJMc2013020
- Clohisey S, Baillie JK. Host susceptibility to severe influenza A virus infection. Crit Care. 2019;23(1):303. doi: 10.1186/s13054-019-2566-7
- Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4570. doi: 10.1126/science.abd4570
- Kaser A. Genetic risk of severe Covid-19. N Engl J Med. 2020;383(16):1590–1591. doi: 10.1056/NEJMe2025501
- Ellinghaus D, Degenhardt F, Bujanda L, et al; Severe COVID-19 GWAS Group. Genomewide association study of severe COVID-19 with respiratory failure. N Engl J Med. 2020;383(16):1522–1534. doi: 10.1056/NEJMoa2020283
- Pairo-Castineira E, Clohisey S, Klaric L, et al. Genetic mechanisms of critical illness in Covid-19. Nature. 2021;591(7848):92–98. doi: 10.1038/s41586-020-03065-y
- Zhou S, Butler-Laporte G, Nakanishi T, et al. A Neanderthal OAS1 isoform protects against COVID-19 susceptibility and severity: results from mendelian randomization and case-control studies. medRxiv. 2020. doi: 10.1101/2020.10.13.20212092
- Zeberg H, Pääbo S. The major genetic risk factor for severe COVID-19 is inherited from Neanderthals. Nature. 2020b;587(7835):610–612. doi: 10.1038/s41586-020-2818-3
- Zeberg H, Pääbo S. A genomic region associated with protection against severe COVID-19 is inherited from Neandertals. Proc Natl Acad Sci USA. 2021;118(9):e2026309118. doi: 10.1073/pnas.2026309118
- WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for Covid-19 – Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384(6):497–511. doi: 10.1056/NEJMoa2023184
- Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–1418. doi: 10.1016/S0140-6736(20)30937-5
- Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020a;5(5):428–430. doi: 10.1016/S2468-1253(20)30057-1
- Zhou Z, Ren L, Zhang L, et al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe. 2020;27(6):883–890.e2. doi: 10.1016/j.chom.2020.04.017
- Hamming I, Timens WM, Bulthuis LC, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–637. doi: 10.1002/path.1570
- Jia H, Thelwell C, Dilger P, et al. Endothelial cell functions impaired by interferon in vitro: Insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy. Thromb Res. 2018;163:105–116. doi: 10.1016/j.thromres.2018.01.039
- Stebbing J, Sánchez Nievas G, Falcone M, et al. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci Adv. 2021;7(1):eabe4724. doi: 10.1126/sciadv.abe4724
- Kuo CL, Pilling LC, Atkins JL, et al. APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort. J Gerontol A Biol Sci Med Sci. 2020;75(11):2231–2232. doi: 10.1093/gerona/glaa131
- Gemmati D, Bramanti B, Serino ML, et al. COVID-19 and individual genetic susceptibility/receptivity: role of ACE1/ACE2 genes, immunity, inflammation and coagulation. Might the double X-chromosome in females be protective against SARS-CoV-2 compared to the single X-chromosome in males? Int J Mol Sci. 2020;21(10):3474. doi: 10.3390/ijms21103474
- Li Y, Zhang Z, Yang L, et al. The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike. Science. 2020b;23(8):101400. doi: 10.1016/j.isci.2020.101400
- Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17(1):11–30. doi: 10.1038/s41574-020-00435-4
- Zeberg H, Pääbo S. The MERS-CoV receptor gene is among COVID-19 risk factors inherited from Neandertals. bioRxiv. 2020c. doi: 10.1101/2020.12.11.422139
- Long SW, Olsen RJ, Christensen PA, et al. Molecular architecture of early dissemination and massive second wave of the SARS-CoV-2 virus in a major metropolitan area. mBio. 2020;11(6):e02707-20. doi: 10.1128/mBio.02707-20
- Plante JA, Liu Y, Liu J, et al. Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility. bioRxiv. 2020;2020.09.01.278689. doi: 10.1101/2020.09.01.278689
- Shannon A, Le NT, Selisko B, et al. Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 exonuclease active-sites. Antiviral Res. 2020;178:104793. doi: 10.1016/j.antiviral.2020.104793
- Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNAdependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020;295(20):6785–6797. doi: 10.1074/jbc.RA120.013679
- Chan AP, Choi Y, Schork NJ. Conserved genomic terminals of SARS-CoV-2 as coevolving functional elements and potential therapeutic targets. mSphere. 2020;5(6):e00754-20. doi: 10.1128/mSphere.00754-20
- Mishra A, Pandey AK, Gupta P, et al. Mutation landscape of SARS-CoV-2 reveals three mutually exclusive clusters of leading and trailing single nucleotide substitutions. bioRxiv. 2020. doi: 10.1101/2020.05.07.082768
- Meini S, Zanichelli A, Sbrojavacca R, et al. Understanding the pathophysiology of COVID-19: could the contact system Be the key? Front Immunol. 2020;11:2014. doi: 10.3389/fimmu.2020.02014
- Girardi E, López P, Pfeffer S. On the importance of host microRNAs during viral infection. Front Genet. 2018;9:439. doi: 10.3389/fgene.2018.00439
- Khan MA, Sany MR, Islam MS, Islam A. Epigenetic regulator miRNA pattern differences among SARS-CoV, SARS-CoV-2, and SARS-CoV-2 world-wide isolates delineated the mystery behind the epic pathogenicity and distinct clinical characteristics of pandemic COVID-19. Front Genet. 2020;11:765. doi: 10.3389/fgene.2020.00765
- Bavagnoli L, Campanini G, Forte M, et al. Identification of a novel antiviral micro-RNA targeting the NS1 protein of the H1N1 pandemic human influenza virus and a corresponding viral escape mutation. Antiviral Res. 2019;171:104593. doi: 10.1016/j.antiviral.2019.104593
- Herrera-Rivero M, Zhang R, Heilmann-Heimbach S, et al. Circulating microRNAs are associated with pulmonary hypertension and development of chronic lung disease in congenital diaphragmatic hernia. Sci Rep. 2018;8(1):10735. doi: 10.1038/s41598-018-29153-8
- Qiu X, Dou Y. miR-1307 promotes the proliferation of prostate cancer by targeting FOXO3A. Biomed Pharmacother. 2017;88:430–435. doi: 10.1016/j.biopha.2016.11.120
- Balmeh N, Mahmoudi S, Mohammadi N, Karabedianhajiabadi A. Predicted therapeutic targets for COVID-19 disease by inhibiting SARS-CoV-2 and its related receptors. Inform Med Unlocked. 2020;20:100407. doi: 10.1016/j.imu.2020.100407
- Ortuso F, Mercatelli D, Guzzi PH, Giorgi F. Structural genetics of circulating variants affecting the SARS-CoV-2 spike/human ACE2 complex. J Biomol Struct Dyn. 2021;1–11. doi: 10.1080/07391102.2021.1886175
- Kemp SA, Collier DA, Datir RP, et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021. doi: 10.1038/s41586-021-03291-y
- Young BE, Fong SW, Chan YH, et al. Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study. Lancet. 2020;396(10251):603–611. doi: 10.1016/S0140-6736(20)31757-8
- To KK, Hung IF, Ip JD, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis. 2020:ciaa1275. doi: 10.1093/cid/ciaa1275
- Tillett RL, Sevinsky JR, Hartley PD, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2021;21(1):52–58. doi: 10.1016/S1473-3099(20)30764-7
- Dos Santos LA, de Góis Filho PG, Fantini Silva AM, et al. Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers. J Infect. 2021;82(3):399–406. doi: 10.1016/j.jinf.2021.01.020
- McCarthy KR, Rennick LJ, Nambulli S, et al. Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. Science. 2021;371(6534):1139–1142. doi: 10.1126/science.abf6950
- Shkurnikov M, Nersisyan S, Jankevic T, et al. Association of HLA class I genotypes with severity of Coronavirus Disease-19. Front Immunol. 2021;12:641900. doi: 10.3389/fimmu.2021.641900
- Pisanti S, Deelen J, Gallina AM, et al. Correlation of the two most frequent HLA haplotypes in the Italian population to the differential regional incidence of Covid-19. J Transl Med. 2020;18(1):352. doi: 10.1186/s12967-020-02515-5